tradingkey.logo
tradingkey.logo
Search

Teleflex’s Freesolve™ RMS Receives FDA Breakthrough Device Designation

TradingKeyOct 22, 2026 10:51 AM
facebooktwitterlinkedin
View all comments(0)

The U.S. Food and Drug Administration has granted Breakthrough Device Designation to Teleflex Incorporated’s Freesolve™ Resorbable Magnesium Scaffold for percutaneous coronary intervention. This designation recognizes technologies addressing unmet clinical needs for life-threatening conditions. Teleflex is currently conducting the BIOMAG™-III Pivotal Trial to support a future U.S. FDA Premarket Approval application. Together, the designation and ongoing clinical evaluation may accelerate the future commercial availability of the Freesolve™ RMS device in the United States market, enhancing the company’s cardiovascular product portfolio and strategic positioning in advanced coronary interventions.

AI-generated summary

Teleflex Incorporated (NYSE: TFX) announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to the company’s Freesolve™ Resorbable Magnesium Scaffold for percutaneous coronary intervention, or PCI.

Freesolve™ Resorbable Magnesium Scaffold is also referred to as Freesolve™ RMS. To qualify for Breakthrough Device Designation, a device technology must address an unmet clinical need and show the potential to provide more effective treatment for life-threatening or irreversibly debilitating diseases or conditions.

Teleflex is also conducting the BIOMAG™-III Pivotal Trial (NCT07258290), which is designed to support a future U.S. FDA Premarket Approval application. Together with the ongoing trial, the designation may support the future commercial availability of Freesolve™ RMS in the United States.

This article may include AI-generated content that is human-reviewed, which is for reference and general information purposes only and does not constitute investment advice.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.